PAREXEL Collaborates With Sanofi on Wearable Devices

LONDON, June 15, 2017 - PAREXEL International Corporation, a global biopharmaceutical services organization, announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials.

Wearables have the potential to address several challenges related to clinical trials and improve execution by increasing patients’ ability to participate, driving patient engagement, and creating more opportunities for decentralised trial sites. The PAREXEL-Sanofi collaboration is designed to further explore the potential of patient sensors and wearable devices to remotely collect patient data during clinical trials.

The two companies are jointly leveraging their clinical, scientific, regulatory, logistics and technical expertise, as well as global footprint, to determine how wearables can optimise study performance and accelerate drug development. In particular, the companies are examining how data collected from several wearable devices can be streamlined into a single, scalable data system to provide valuable insights.

Currently, PAREXEL and Sanofi are collaborating on a pilot study using PAREXEL’s recently launched patient sensor solution to demonstrate the scientific and medical viability of wearables. In an ongoing single-site study, patient data is being collected remotely and simultaneously via multiple wearable devices. Publication of final study results is expected in the near future.

“We believe the use of wearables to collect data from trial participants represents a breakthrough in the digital transformation within the industry,” said Xavier Flinois, President, PAREXEL Informatics. “Working with Sanofi, we believe we have a strong opportunity to streamline and automate data collection from multiple devices, collect high-quality data remotely and generate meaningful results, all while reducing burden on patients and sites, as well as lowering costs.”

“Our objective is to demonstrate the relevance of data collected remotely and the overall feasibility of utilising wearables in clinical trials,” said Lionel Bascles, Global Head of Clinical Sciences and Operations of Sanofi. “Wearables are a core component of Sanofi’s digital trials strategy, and represent an important approach to automate patient processes using the latest technologies to bring new therapies to patients sooner. We are pleased to be collaborating with PAREXEL and leveraging their multi-functional expertise in this area. We are committed to further advancing the potential of this technology.”

PAREXEL’s recently launched patient sensor solution, powered by the Perceptive MyTrials® Analytics platform, facilitates the remote collection of study subject data. To deliver this solution, PAREXEL has partnered with leading technology providers to capture, securely transmit, store, and monitor data, as well as generate alerts based on the potentially large volume of time-series data from sensors.

About PAREXEL International 
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL Contacts:

Media:
Sophie Marston/ Ivelina Adzheva
OneChocolate for PAREXEL
Tel.: 0207 437 0227
Email: PAREXEL@onechocolatecomms.co.uk

Investors:
Ronald Aldridge
Tel.: +1 781-434-4753
Email: Ron.Aldridge@PAREXEL.com